DERM stock is starting Monday off with a bang. After Dermira, Inc. (NASDAQ:DERM) announced news of a positive trial of dermatitis treatment, shares of the biotech company soared. At the time of writing, DERM stock is up nearly 100%.
DERM Stock Up After Positive Trial ResultsOn Monday, Dermira, Inc. announced that its phase 2b trial of Lebrikizumab met primary endpoints, resulting in a positive mid-stage trial. Using Lebrikizumab, which is an “injectable, humanized monoclonal antibody,” according to MarketWatch, the trial demonstrated improvements in the EASI score. For perspective, these results are in comparison to a ...
Read The Full Article On MicroSmallCap.com
Get early insight on hidden secret gems on MicroSmallCap. Follow Crypto, Mining, Cannabis and Energy stocks and get free research reports here.
All content provided by MicroSmallCap is subject to our Terms Of Use and Disclaimer.